Amneal Pharmaceuticals, Inc. AMRX Specialty — Selling General And Administrative Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — selling general and administrative expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s specialty — selling general and administrative expense?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — selling general and administrative expense of $34.69M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s specialty — selling general and administrative expense changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s specialty — selling general and administrative expense increased by 12.0% year-over-year, from $30.98M to $34.69M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — selling general and administrative expense?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — selling general and administrative expense has grown at a 12.6% compound annual growth rate (CAGR), from $84.48M to $135.72M.
- What does specialty — selling general and administrative expense mean?
- Encompasses the costs of marketing, sales force operations, and general administrative support required to manage the specialty business segment. This metric highlights the operational leverage of the segment and the efficiency of its commercialization efforts. Investors use this to evaluate how effectively the company converts its specialty product portfolio into market share.